Week in Review: GSK Ends China Bribery Investigation by Paying $489 Million Fine

GlaxoSmithKline will pay a $489 million fine to settle the long-running China investigation into its practice of bribing doctors, a record high punishment for China; CASI Pharma in-licensed China rights to three cancer products from Spectrum Pharma in a deal worth $11.5 million; BeiGene received a $9 million milestone from Merck Serono for starting a Phase I trial of a partnered drug; Denovo Biopharma, a US-China company, acquired global rights to enzastaurin, a late-clinical-stage oncology drug from Eli Lilly; BGI of Shenzhen and the Vancouver Prostate Center created a sequencing and translational research facility to improve cancer care; 3SBio acquired an exclusive China license to develop JenKem's PEG-irinotecan, a chemotherapy; CSPC Zhongqi Pharma will underwrite drug discovery work at Columbia University of New York City; and Milestone Scientific, a US medical device company, will form a JV with Milestone China to develop a painless botox injection system. More details.... Stock Symbols: (NYSE: GSK) (NSDQ: CASI) (NSDQ: SPPI) (XETRA: MRK) (NYSE: LLY) (OTCQB: MLSS) Share this with colleagues: // //